

Michael Fx Gnant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660992/publications.pdf>

Version: 2024-02-01

609
papers

49,525
citations

4383

86
h-index

1796

211
g-index

640
all docs

640
docs citations

640
times ranked

36874
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	3.2	17
2	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	0.8	25
3	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
4	Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2022, 23, 195-197.	5.1	4
5	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392.	5.1	107
6	Abstract P5-13-36: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36.	0.4	0
7	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022, 82, GS1-07-GS1-07.	0.4	0
8	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , 2022, 82, PD2-04-PD2-04.	0.4	0
9	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. <i>Cancer Research</i> , 2022, 82, P1-02-07-P1-02-07.	0.4	0
10	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). <i>Cancer Research</i> , 2022, 82, P4-10-01-P4-10-01.	0.4	1
11	Abstract DEB1-1: Pro - RxPONDER: Was it all OFS?. <i>Cancer Research</i> , 2022, 82, DEB1-1-DEB1-1.	0.4	0
12	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. <i>Cancer Research</i> , 2022, 82, P4-06-08-P4-06-08.	0.4	0
13	Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. <i>Cancer Research</i> , 2022, 82, P4-12-01-P4-12-01.	0.4	0
14	Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. <i>ESMO Open</i> , 2022, 7, 100426.	2.0	2
15	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	0.9	22
16	The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. <i>International Journal of Surgery</i> , 2022, 104, 106694.	1.1	4
17	A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10616-TPS10616.	0.8	2
18	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. Journal of Clinical Oncology, 2022, 40, 518-518.	0.8	4
20	Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project.. Journal of Clinical Oncology, 2022, 40, e13639-e13639.	0.8	0
21	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clinical Breast Cancer, 2021, 21, 80-91.e7.	1.1	140
22	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	5.1	49
23	St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care, 2021, 16, 135-143.	0.8	90
24	A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort. ESMO Open, 2021, 6, 100006.	2.0	7
25	PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. British Journal of Surgery, 2021, 108, 308-314.	0.1	19
26	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	5.1	169
27	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. British Journal of Cancer, 2021, 124, 1795-1802.	2.9	3
28	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. Journal of Clinical Oncology, 2021, 39, 518-518.	0.8	2
29	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer- The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	0.8	153
30	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. New England Journal of Medicine, 2021, 385, 395-405.	13.9	82
31	ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. ESMO Open, 2021, 6, 100228.	2.0	11
32	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. Clinical Cancer Research, 2021, 27, 5931-5938.	3.2	1
33	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13-864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	5.1	147
34	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
35	Fifteen Years of Breast Care. Breast Care, 2021, 16, 97-98.	0.8	0
36	Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care. JCO Global Oncology, 2021, 7, 1513-1521.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 610-618.	0.9	100
38	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncologica</i> , 2020, 59, 75-81.	0.8	10
39	The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 2017-2024.	0.7	11
40	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	2.0	14
41	More is not always better—what can be learned from the D-CARE trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1034-1034.	0.7	2
42	Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542093845.	0.8	3
43	Knowledge gaps in oncoplastic breast surgery. <i>Lancet Oncology</i> , The, 2020, 21, e375-e385.	5.1	34
44	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	2.0	113
45	Virtual Science in Senology: Let Us Not Throw out the Baby with the Bathwater. <i>Breast Care</i> , 2020, 15, 323-324.	0.8	0
46	Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Positive Trial. <i>BMC Cancer</i> , 2020, 20, 392.	1.1	27
47	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 545-555.	1.4	5
48	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoadjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	1.3	29
49	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	3.2	4
50	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	3.2	22
51	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020, 50, 64-70.	0.9	12
52	Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. <i>European Journal of Cancer</i> , 2020, 127, 12-20.	1.3	26
53	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 87-96.	1.1	6
54	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24

#	ARTICLE	IF	CITATIONS
55	IDO1+ Paneth cells promote immune escape of colorectal cancer. <i>Communications Biology</i> , 2020, 3, 252.	2.0	26
56	LM02-trial perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16046-e16046.	0.8	0
57	Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 588-588.	0.8	1
58	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	5.1	76
59	Challenges and Controversies in Breast Surgery. <i>Breast Care</i> , 2019, 14, 185-187.	0.8	4
60	Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial. <i>Breast</i> , 2019, 44, S79.	0.9	0
61	New evidence and hope for young patients with breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 166-168.	1.3	0
62	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. <i>Annals of Oncology</i> , 2019, 30, 1541-1557.	0.6	464
63	Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 1807-1815.	6.3	259
64	The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer. <i>Cells</i> , 2019, 8, 1357.	1.8	6
65	OC-0270 Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial. <i>Radiotherapy and Oncology</i> , 2019, 133, S132-S133.	0.3	1
66	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
67	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. <i>Annals of Oncology</i> , 2019, 30, 567-574.	0.6	19
68	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
69	Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. <i>Breast</i> , 2019, 46, 101-107.	0.9	5
70	The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 111-124.	0.7	10
71	Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0215915.	1.1	57
72	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 ⁺ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54

#	ARTICLE	IF	CITATIONS
73	Denosumab in early-stage breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, 236.	5.1	2
74	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	1.1	61
75	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
76	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019, 14, 103-110.	0.8	131
77	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260
78	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 339-351.	5.1	167
79	ERR1± promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. <i>Oncogene</i> , 2019, 38, 950-964.	2.6	25
80	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 2737-2744.	3.2	34
81	Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. <i>Annals of Oncology</i> , 2019, 30, 109-114.	0.6	15
82	Impact of Breast Surgery in Primary Metastasized Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 1163-1169.	2.1	130
83	Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years. , 2019, , .		1
84	Exploratory analysis of the effect of taselelisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1050-1050.	0.8	1
85	Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 553-553.	0.8	3
86	Abstract P1-17-05: The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer. , 2019, , .		0
87	Abstract P2-08-04: Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET). , 2019, , .		0
88	Abstract P2-13-01: Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial. , 2019, , .		2
89	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1435226.	2.1	36
90	Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy. <i>British Journal of Surgery</i> , 2018, 105, 811-819.	0.1	33

#	ARTICLE	IF	CITATIONS
91	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.4	50
92	Explained variation in shared frailty models. <i>Statistics in Medicine</i> , 2018, 37, 1482-1490.	0.8	2
93	Reply to "The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.. <i>Annals of Oncology</i> , 2018, 29, 281-282.	0.6	3
94	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
95	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 18.	1.3	12
96	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. <i>Gastroenterology</i> , 2018, 154, 1543-1545.	0.6	27
97	A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 1345-1352.	1.0	7
98	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39.	5.1	717
99	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
100	Systemic Immune-Inflammation Index Predicting Poor Outcome in Pancreatic Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2018, 227, e180.	0.2	0
101	Prognostic Index, but Not Body Composition, Is an Accurate Tool for Preoperative Outcome Estimation in Patients with Primary Resectable Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2018, 227, e21-e22.	0.2	0
102	No Difference of the Systemic Immune-Inflammation Index as Prognostic Factor for Patients with Adenocarcinoma of the Gastroesophageal Junction With or Without Neoadjuvant Treatment. <i>Journal of the American College of Surgeons</i> , 2018, 227, S245-S246.	0.2	0
103	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 78-86.	1.8	36
104	Pro-angiogenic profile after resection of primary tumour might be responsible for reduced outcome in patients with primary metastasized breast cancer. <i>European Journal of Cancer</i> , 2018, 92, S137.	1.3	0
105	Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone " A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0206911.	1.1	12
106	The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 1210.	1.1	26
107	Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. <i>Trials</i> , 2018, 19, 667.	0.7	73
108	Three-60 Criteria: A Novel Definition of Post-Resectional Liver Dysfunction with Improved Predictive Potential. <i>Journal of the American College of Surgeons</i> , 2018, 227, S182.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Elevated Mean Corpuscular Volume Predicts Poor Outcome in Patients With Adenocarcinomas of the Esophagogastric Junction. <i>Journal of the American College of Surgeons</i> , 2018, 227, e215.	0.2	0
110	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. <i>Annals of Surgery</i> , 2018, 268, 894-902.	2.1	69
111	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	1.1	84
112	“Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed” mutation rate of the marker higher than expected. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018, 50, 160-166.	0.3	5
113	Toward a Consensus on Centralization in Surgery. <i>Annals of Surgery</i> , 2018, 268, 712-724.	2.1	187
114	TP53 is not a prognostic marker” clinical consequences of a generally disregarded fact. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 46-53.	1.8	2
115	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 500-500.	0.8	23
116	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. <i>Journal of Clinical Oncology</i> , 2018, 36, 538-538.	0.8	1
117	Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselesib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer. , 2018, , .		0
118	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 524-524.	0.8	2
119	High prevalence of dyslipidemia but insufficient statin use in patients with non-cirrhotic and cirrhotic liver disease. , 2018, 56, .		0
120	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	3.2	29
121	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	0.8	87
122	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017, 7, 1-12.	1.0	181
123	Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 421-427.	1.1	21
124	St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. <i>Breast Care</i> , 2017, 12, 101-106.	0.8	109
125	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
126	Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study). <i>European Journal of Cancer</i> , 2017, 72, S3.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2+ breast cancer: subgroup analysis of STEPAUT. <i>Breast</i> , 2017, 32, S26-S27.	0.9	0
128	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
129	Breast cancer. <i>Lancet</i> , The, 2017, 389, 1134-1150.	6.3	1,568
130	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
131	Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 555-556.	0.7	5
132	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	0.6	844
133	Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 116-122.	1.8	3
134	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). <i>Annals of Oncology</i> , 2017, 28, v605.	0.6	103
135	Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer. , 2017, , .		1
136	Abstract P4-22-20: Efficacy and safety of everolimus plus exemestane in HR+, HER2+ advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2ndinterim analysis from STEPAUT. , 2017, , .		5
137	SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 503-503.	0.8	9
138	Primary operation in synchronous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIME trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 557-557.	0.8	6
139	ASAMET: A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1591-TPS1591.	0.8	2
140	Inflammatory response and oxidative stress during liver resection. <i>PLoS ONE</i> , 2017, 12, e0185685.	1.1	23
141	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. <i>Anticancer Research</i> , 2017, 37, 2683-2691.	0.5	10
142	Adjuvant Treatment with Bone-Targeting Agents (Bisphosphonates and Anti-RANK-Ligand Antibody). , 2017, , 593-598.		0
143	Primary surgery versus no surgery in synchronous metastatic breast cancer: Patient-reported outcomes of the ABCSG 28 Positive trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1074-1074.	0.8	0
144	Independent validation of stromal uPA in archived tumor samples from the prospectively randomized ABCSG8 trial to provide level 1b evidence for a prognostic value of uPA immunohistochemistry in endocrine-treated postmenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-536.	0.8	7

#	ARTICLE	IF	CITATIONS
145	High accumulation of metformin in colonic tissue of subjects with diabetes or metabolic syndrome.. Journal of Clinical Oncology, 2017, 35, 1557-1557.	0.8	0
146	Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment, 2016, 157, 91-99.	1.1	22
147	Editorial comment on "Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials". European Journal of Cancer, 2016, 59, 125-127.	1.3	1
148	Pathological complete remission and long-term outcome"what do we know in 2016?. Lancet Oncology, The, 2016, 17, 693-694.	5.1	3
149	Prognostic value of <sc>HMGB</sc> 1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Medicine, 2016, 5, 2350-2358.	1.3	34
150	Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncology, 2016, 2, 1310.	3.4	395
151	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 1888.	3.8	79
152	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. Clinical Journal of Oncology Nursing, 2016, 20, 175-180.	0.3	12
153	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 70-75.	0.3	0
154	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 367-377.	5.1	444
155	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 2016, 27, 379-390.	0.6	165
156	Palbociclib for the treatment of postmenopausal breast cancer " an update. Expert Opinion on Pharmacotherapy, 2016, 17, 255-263.	0.9	15
157	Adjuvant Bisphosphonates and Breast Cancer Survival. Annual Review of Medicine, 2016, 67, 1-10.	5.0	20
158	Abstract OT1-03-21: PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. , 2016, , .		3
159	Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial. , 2016, , .		3
160	Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. Cancer Research, 2016, 76, S2-02-S2-02.	0.4	19
161	Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy"based regimens. , 2016, , .		7
162	PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.. Journal of Clinical Oncology, 2016, 34, 1002-1002.	0.8	2

#	ARTICLE	IF	CITATIONS
163	The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxelâ€”Health-related quality of life during ongoing therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1035-1035.	0.8	2
164	LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS613-TPS613.	0.8	3
165	Abstract B28: Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer.., 2016, , .		0
166	Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patients. , 2016, , .		0
167	Abstract P2-08-21: Stromal co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. , 2016, , .		0
168	Abstract OT1-03-06: LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. , 2016, , .		0
169	Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTO trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 604-604.	0.8	1
170	2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases. <i>European Journal of Cancer</i> , 2015, 51, S592.	1.3	0
171	268 Epirubicin/docetaxel induced immunogenic cell death correlates with response to therapy and with extended disease-free survival. <i>European Journal of Cancer</i> , 2015, 51, S49.	1.3	0
172	Breast Cancer Is Our Global Responsibility. <i>Breast Care</i> , 2015, 10, 360-360.	0.8	6
173	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015, 112, 1405-1410.	2.9	68
174	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 433-443.	6.3	444
175	Does patient education work in breast cancer? Final results from the global CARIATIDE study. <i>Future Oncology</i> , 2015, 11, 205-217.	1.1	23
176	CDK4/6 inhibitors in luminal breast cancer. <i>Lancet Oncology, The</i> , 2015, 16, 2-3.	5.1	7
177	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	1.1	4
178	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015, 26, 1685-1691.	0.6	108
179	Final 10-year results of the Breast International Group 2â€”98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
180	St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. <i>Breast Care</i> , 2015, 10, 124-130.	0.8	82

#	ARTICLE	IF	CITATIONS
181	PG 4.03 Targeting bone microenvironment: clinical implications. Breast, 2015, 24, S8-S9.	0.9	0
182	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics, 2015, 33, 179-190.	1.7	22
183	Tailoring therapiesâ€”improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
184	Reply to the letter to the editor â€”Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patientsâ€™ by Fouad et al.. Annals of Oncology, 2015, 26, 1799-1800.	0.6	0
185	Bevacizumab: no comeback in early breast cancer?. Lancet Oncology, The, 2015, 16, 1001-1003.	5.1	3
186	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Medical Genomics, 2015, 8, 54.	0.7	352
187	St.Gallen-2015 in Vienna: News from a successful breast cancer conference transposition!. Breast, 2015, 24, S1.	0.9	0
188	Morbidity reduction using the vessel sealing device LigaSureâ„¢ in breast cancer surgery. European Surgery - Acta Chirurgica Austriaca, 2015, 47, 150-156.	0.3	2
189	Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clinical and Experimental Metastasis, 2015, 32, 729-737.	1.7	103
190	TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients. EBioMedicine, 2015, 2, 825-830.	2.7	37
191	Targeting bone microenvironment: Clinical implications. Breast, 2015, 24, S49-S50.	0.9	1
192	Denosumab and fracture risk in women with breast cancer â€” Author's reply. Lancet, The, 2015, 386, 2057-2058.	6.3	6
193	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology, 2015, 26, 313-320.	0.6	251
194	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. Journal of Clinical Oncology, 2015, 33, 916-922.	0.8	189
195	Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases. , 2015, , 685-689.		0
196	Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study. , 2015, , .		3
197	Abstract P6-16-10: Activity of T-DM1 in HER2-positive breast cancer brain metastases. , 2015, , .		1
198	Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. , 2015, , .		14

#	ARTICLE	IF	CITATIONS
199	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. Journal of Clinical Oncology, 2015, 33, 504-504.	0.8	6
200	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. Journal of Clinical Oncology, 2015, 33, 508-508.	0.8	16
201	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. Journal of Clinical Oncology, 2015, 33, 551-551.	0.8	1
202	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. Journal of Clinical Oncology, 2015, 33, 117-117.	0.8	1
203	Abstract P6-08-47: Androgen receptor expression in pre-menopausal early breast cancer patients treated with endocrine therapy within the ABCSG-12 trial - a single center pilot analysis. , 2015, , .		0
204	Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer. , 2015, , .		0
205	Abstract P5-18-01: TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial. , 2015, , .		0
206	Prognostic impact of breast cancer (BC) subtype in elderly patients.. Journal of Clinical Oncology, 2015, 33, e20536-e20536.	0.8	0
207	Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases. Annals of Oncology, 2014, 25, iv122.	0.6	0
208	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Modern Pathology, 2014, 27, 906-915.	2.9	21
209	The AURORA initiative for metastatic breast cancer. British Journal of Cancer, 2014, 111, 1881-1887.	2.9	77
210	Evaluation of Soluble E-Cadherin as a Predictive Marker for Response to Preoperative Systemic Chemotherapy in Early Breast Cancer. Annals of Oncology, 2014, 25, i18.	0.6	0
211	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care, 2014, 9, 6-6.	0.8	8
212	The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2 ⁺ early breast cancer. British Journal of Cancer, 2014, 111, 837-842.	2.9	36
213	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology, 2014, 25, 808-815.	0.6	112
214	The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. Clinical Cancer Research, 2014, 20, 1298-1305.	3.2	182
215	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology, 2014, 25, 366-371.	0.6	62
216	1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2 ⁻) advanced breast cancer (BC): overall survival results from BOLERO-2. European Journal of Cancer, 2014, 50, S1.	1.3	14

#	ARTICLE	IF	CITATIONS
217	The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of Aromatase Inhibitors Assessment In Daily practice through Educational approach (CARIATIDE) study. <i>Breast</i> , 2014, 23, 393-399.	0.9	44
218	Role of bisphosphonates in postmenopausal women with breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 476-484.	3.4	28
219	HER2-positive breast cancer: a new piece of the puzzle. <i>Lancet Oncology</i> , The, 2014, 15, 668-669.	5.1	2
220	Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections. <i>World Journal of Surgery</i> , 2014, 38, 456-462.	0.8	10
221	Impact of the Reconstruction Method on Delayed Gastric Emptying After Pylorus-Preserving Pancreaticoduodenectomy: A Prospective Randomized Study. <i>World Journal of Surgery</i> , 2014, 38, 465-475.	0.8	44
222	Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 52-59.	0.9	12
223	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. <i>Lancet</i> , The, 2014, 383, 2127-2135.	6.3	1,701
224	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 771-778.	1.1	22
225	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 59-70.	0.5	7
226	890: Plasma levels of cell death biomarker HMGB1 during the first cycle of epirubicin/docetaxel or 5-FU/oxaliplatin. <i>European Journal of Cancer</i> , 2014, 50, S217.	1.3	0
227	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. <i>Annals of Oncology</i> , 2014, 25, 339-345.	0.6	326
228	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 2357-2362.	0.6	446
229	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014, 23, 637-643.	0.9	56
230	Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification. <i>International Journal of Surgery</i> , 2014, 12, 334-339.	1.1	46
231	Modern Therapeutic Concepts of Early Breast Cancer. <i>Breast Care</i> , 2014, 9, 85-85.	0.8	1
232	Interview: Aspects of modern breast cancer management: a surgeon's tale. <i>Breast Cancer Management</i> , 2014, 3, 139-143.	0.2	0
233	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1008-1008.	0.8	5
234	Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	0.8	1

#	ARTICLE	IF	CITATIONS
235	Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).. Journal of Clinical Oncology, 2014, 32, 529-529.	0.8	5
236	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. Journal of Clinical Oncology, 2014, 32, 577-577.	0.8	4
237	T-DM1 in HER2-positive breast cancer brain metastases (BM).. Journal of Clinical Oncology, 2014, 32, 650-650.	0.8	1
238	A cross-section study evaluating patients'™ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. Journal of Clinical Oncology, 2014, 32, e17574-e17574.	0.8	1
239	Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2- mutant or wild-type, breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, TPS655-TPS655.	0.8	1
240	A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Anticancer Research, 2014, 34, 2377-84.	0.5	15
241	Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer—a phase II clinical trial. Anticancer Research, 2014, 34, 6767-73.	0.5	27
242	Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. European Surgery - Acta Chirurgica Austriaca, 2013, 45, 169-178.	0.3	1
243	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Critical Reviews in Oncology/Hematology, 2013, 87, 101-111.	2.0	46
244	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. European Journal of Clinical Investigation, 2013, 43, 277-285.	1.7	59
245	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
246	Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. British Journal of Cancer, 2013, 109, 1522-1527.	2.9	41
247	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. Clinical Breast Cancer, 2013, 13, 421-432.e8.	1.1	104
248	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. Journal of the National Cancer Institute, 2013, 105, 654-663.	3.0	88
249	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 2013, 30, 870-884.	1.3	430
250	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer, 2013, 119, 1908-1915.	2.0	81
251	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. European Journal of Cancer, 2013, 49, 2621-2632.	1.3	53
252	The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer. Current Oncology Reports, 2013, 15, 14-23.	1.8	20

#	ARTICLE	IF	CITATIONS
253	Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>British Journal of Cancer</i> , 2013, 108, 2259-2263.	2.9	48
254	The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. <i>British Journal of Cancer</i> , 2013, 109, 589-596.	2.9	57
255	Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. <i>British Journal of Cancer</i> , 2013, 108, 1408-1414.	2.9	25
256	4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013, 45, 277-281.	0.3	0
257	St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion. <i>Breast Care</i> , 2013, 8, 102-109.	0.8	123
258	Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion. <i>Breast Care</i> , 2013, 8, 293-299.	0.8	15
259	CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. <i>Clinical Cancer Research</i> , 2013, 19, 500-507.	3.2	107
260	Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2013, 18, 353-361.	1.9	67
261	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. <i>Annals of Oncology</i> , 2013, 24, 640-647.	0.6	170
262	Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer. <i>Breast Journal</i> , 2013, 19, 149-155.	0.4	17
263	Plasma HMGB1 after the initial dose of epirubicin/docetaxel in cancer. <i>European Journal of Clinical Investigation</i> , 2013, 43, 286-291.	1.7	29
264	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2 ⁻ breast cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2959-2964.	2.9	288
265	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	0.9	24
266	Guidelines: Usefulness and Limitations. <i>Breast Care</i> , 2013, 8, 172-173.	0.8	2
267	Follow-Up after Breast Cancer Diagnosis. <i>Breast Care</i> , 2013, 8, 457-460.	0.8	2
268	Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13). , 2013, , .		9
269	Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. , 2013, , .		1
270	Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. <i>Cancer Research</i> , 2013, 73, S4-07-S4-07.	0.4	37

#	ARTICLE	IF	CITATIONS
271	Abstract S5-05: Postneoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer – The phase III NATAN study (GBC) Tj ETQq1 1 0.784314 rgBT		
272	Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.. Journal of Clinical Oncology, 2013, 31, 506-506.	0.8	8
273	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 553-553.	0.8	2
274	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 561-561.	0.8	5
275	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. Journal of Clinical Oncology, 2013, 31, e11601-e11601.	0.8	3
276	BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.. Journal of Clinical Oncology, 2013, 31, 152-152.	0.8	3
277	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 155-155.	0.8	2
278	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 557-557.	0.8	0
279	Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 573-573.	0.8	7
280	A cross-section questionnaire to evaluate patients'™ satisfaction with totally implanted access ports (Port-a-Cath; PAC) and analysis of PAC-related complications at a tertiary care center.. Journal of Clinical Oncology, 2013, 31, e20693-e20693.	0.8	0
281	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	0.8	4
282	BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, 148-148.	0.8	0
283	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 151-151.	0.8	0
284	Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. , 2013, , .		0
285	Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. , 2013, , .		1
286	Abstract PL02: Adjuvant bisphosphonate therapy in breast cancer. , 2013, , .		0
287	Abstract P1-08-13: Predictive value of intrinsic luminal subtypes in premenopausal women with endocrine-responsive early breast cancer: Results from Austrian breast and colorectal cancer study group trial 5. , 2013, , .		0
288	The sequential use of endocrine treatment for advanced breast cancer: where are we?. Annals of Oncology, 2012, 23, 1378-1386.	0.6	53

#	ARTICLE	IF	CITATIONS
289	Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1579-1589.	1.1	21
290	The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. <i>Annals of Oncology</i> , 2012, 23, 2782-2790.	0.6	35
291	Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. <i>Breast Care</i> , 2012, 7, 61-66.	0.8	7
292	Anticancer Activity of Bisphosphonates in Breast Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 114-122.	0.9	5
293	Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 293-298.	0.8	2
294	Brain metastases free survival differs between breast cancer subtypes. <i>British Journal of Cancer</i> , 2012, 106, 440-446.	2.9	74
295	Effects of Bone-Targeted Agents on Cancer Progression and Mortality. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1059-1067.	3.0	171
296	Adjuvant bisphosphonates. <i>Current Opinion in Oncology</i> , 2012, 24, 635-642.	1.1	6
297	Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 722-728.	0.8	91
298	Treatment of Bone Metastases in Patients with Advanced Breast Cancer. <i>Breast Care</i> , 2012, 7, 92-98.	0.8	12
299	8th European Breast Cancer Conference (EBCC-8), Vienna, March 21-24, 2012. <i>Breast Care</i> , 2012, 7, 170-176.	0.8	1
300	Dual inhibition of HER2 in breast cancer treatment. <i>Lancet</i> , 2012, 379, 596-598.	6.3	5
301	253 Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. <i>European Journal of Cancer</i> , 2012, 48, S116.	1.3	3
302	Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 10-13.	0.3	70
303	Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. <i>British Journal of Cancer</i> , 2012, 106, 25-31.	2.9	68
304	Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. <i>Cancer Treatment Reviews</i> , 2012, 38, 407-415.	3.4	147
305	Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 1932-1938.	1.3	47
306	Objectively measured breast symmetry has no influence on quality of life in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2012, 38, 130-136.	0.5	16

#	ARTICLE	IF	CITATIONS
307	Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treatment Reviews, 2012, 38, 798-806.	3.4	78
308	Antiresorptive treatment options and bone health in cancer patientsâ€”safety profiles and clinical considerations. Cancer Treatment Reviews, 2012, 38, 815-824.	3.4	15
309	Everolimus in Postmenopausal Hormone-Receptorâ€”Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	13.9	2,474
310	Entwicklungen der forschenden Pharmaindustrie. Breast Care, 2012, 7, 155-164.	0.8	0
311	Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients. Annals of Surgical Oncology, 2012, 19, 519-526.	0.7	19
312	Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 2012, 134, 237-244.	1.1	90
313	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1508-1516.	0.7	401
314	Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Annals of Surgical Oncology, 2012, 19, 1808-1817.	0.7	49
315	Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?. Current Oncology Reports, 2012, 14, 35-43.	1.8	14
316	Bisphosphonates: Prevention of Bone Metastases in Breast Cancer. Recent Results in Cancer Research, 2012, 192, 65-91.	1.8	25
317	Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study. , 2012, , .		5
318	Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2â” breast cancer patients. Cancer Research, 2012, 72, S4-3-S4-3.	0.4	15
319	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	0.8	3
320	Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, 2012, 30, 512-512.	0.8	4
321	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. Journal of Clinical Oncology, 2012, 30, 542-542.	0.8	1
322	Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. Journal of Clinical Oncology, 2012, 30, 551-551.	0.8	1
323	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 559-559.	0.8	15
324	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, 2012, 30, 102-102.	0.8	2

#	ARTICLE	IF	CITATIONS
325	Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.. Journal of Clinical Oncology, 2012, 30, 104-104.	0.8	3
326	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology, 2012, 30, 125-125.	0.8	4
327	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 99-99.	0.8	2
328	BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology, 2012, 30, 539-539.	0.8	10
329	Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology, 2012, 30, 514-514.	0.8	0
330	BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.. Journal of Clinical Oncology, 2012, 30, 540-540.	0.8	0
331	Abstract P2-13-01: Impact of Body Mass Index (BMI) on the efficacy of aromatase inhibitors to suppress estradiol serum levels in postmenopausal patients with early breast cancer: a prospective proof of principle. , 2012, , .		0
332	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clinical Cancer Research, 2011, 17, 6012-6020.	3.2	597
333	5061 POSTER Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer. European Journal of Cancer, 2011, 47, S348.	1.3	1
334	Discrimination between Circulating Endothelial Cells and Blood Cell Populations with Overlapping Phenotype Reveals Distinct Regulation and Predictive Potential in Cancer Therapy. Neoplasia, 2011, 13, 980-990.	2.3	16
335	Myelosuppression of Thrombocytes and Monocytes Is Associated with a Lack of Synergy between Chemotherapy and Anti-VEGF Treatment. Neoplasia, 2011, 13, 419-427.	2.3	17
336	62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer. Bone, 2011, 48, S17.	1.4	2
337	Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial. European Journal of Cancer, 2011, 47, 6-7.	1.3	25
338	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncology, The, 2011, 12, 631-641.	5.1	427
339	Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific concepts. Breast Disease, 2011, 33, 71-81.	0.4	5
340	Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts. Disease Markers, 2011, 31, 55-65.	0.6	38
341	Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14. Breast Journal, 2011, 17, 230-238.	0.4	6
342	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery, 2011, 149, 311-320.	1.0	101

#	ARTICLE	IF	CITATIONS
343	P286 Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment. <i>Breast</i> , 2011, 20, S69.	0.9	1
344	P305 Neoadjuvant chemotherapy should also be considered for lobular breast cancer. <i>Breast</i> , 2011, 20, S74.	0.9	0
345	P307 Capecitabine (C) for triple-negative early breast cancer (TNBC): Review of available clinical data. <i>Breast</i> , 2011, 20, S75.	0.9	1
346	P345 Updated guidance for the prevention of aromatase inhibitor (AI)-associated bone loss (AIBL) in early breast cancer (EBC). <i>Breast</i> , 2011, 20, S84.	0.9	0
347	BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole. <i>Breast</i> , 2011, 20, S30.	0.9	0
348	Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 121-128.	1.1	29
349	Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 100-107.	1.0	23
350	NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer. <i>World Journal of Surgery</i> , 2011, 35, 1580-1589.	0.8	50
351	Dosing of zoledronic acid throughout the treatment continuum in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 175-188.	2.0	9
352	Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2653-2659.	0.8	196
353	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. <i>Annals of Oncology</i> , 2011, 22, 2546-2555.	0.6	156
354	Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7828-7834.	3.2	13
355	Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data. <i>Clinical Investigation</i> , 2011, 1, 97-107.	0.0	1
356	Adjuvant bisphosphonates – an option with low estrogen?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 698-699.	12.5	1
357	St. Gallen 2011: Summary of the Consensus Discussion. <i>Breast Care</i> , 2011, 6, 136-141.	0.8	194
358	Zoledronic acid in breast cancer: latest findings and interpretations. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 293-301.	1.4	23
359	P1-06-26: The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2~Negative Breast Cancer.. , 2011, , .		2
360	S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor~Positive Early Breast Cancer.. <i>Cancer Research</i> , 2011, 71, S1-2-S1-2.	0.4	30

#	ARTICLE	IF	CITATIONS
361	S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.. <i>Cancer Research</i> , 2011, 71, S3-7-S3-7.	0.4	18
362	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. <i>Journal of Clinical Investigation</i> , 2011, 121, 2000-2012.	3.9	163
363	Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.. <i>Journal of Clinical Oncology</i> , 2011, 29, 520-520.	0.8	12
364	Brain metastasis-free survival in patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 41-41.	0.8	1
365	Quality of life in patients with pancreatic cancer during neoadjuvant chemotherapy using gemcitabine and bevacizumab: A pilot study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 330-330.	0.8	38
366	Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 597-597.	0.8	2
367	Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 572-572.	0.8	1
368	Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 514-514.	0.8	0
369	The role of myelosuppression in synergy between chemotherapy and anti-VEGF treatment.. <i>Journal of Clinical Oncology</i> , 2011, 29, e13527-e13527.	0.8	0
370	Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11058-e11058.	0.8	0
371	Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 111-118.	0.2	0
372	P4-17-05: Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes.. , 2011, , .		1
373	Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. <i>Disease Markers</i> , 2011, 31, 55-65.	0.6	28
374	Potential Anticancer Properties of Bisphosphonates. <i>Seminars in Oncology</i> , 2010, 37, S53-S65.	0.8	63
375	The Evolution of Bone-Targeted Therapies: Introduction. <i>Seminars in Oncology</i> , 2010, 37, S1.	0.8	1
376	The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more â€¦. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, S2-S6.	2.0	10
377	Thrombospondinâ€¦1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1809-1819.	1.9	52
378	Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. <i>British Journal of Cancer</i> , 2010, 103, 1201-1208.	2.9	31

#	ARTICLE	IF	CITATIONS
379	Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?. Journal of Clinical Oncology, 2010, 28, 3548-3551.	0.8	21
380	Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy, 2010, 10, 1825-1836.	1.1	4
381	Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients. Breast Care, 2010, 5, 298-304.	0.8	2
382	Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care, 2010, 5, 158-162.	0.8	11
383	Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study. Onkologie, 2010, 33, 360-368.	1.1	9
384	Breast Cancer: Rank Ligand Inhibition. Breast Care, 2010, 5, 320-325.	0.8	3
385	Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Research, 2010, 12, 216.	2.2	20
386	Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women With Hormone-Responsive Early Breast Cancer. Clinical Breast Cancer, 2010, 10, 267-274.	1.1	11
387	8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer, Supplement, 2010, 8, 60.	2.2	1
388	48 The addition of capecitabine to neoadjuvant chemotherapy for early breast cancer (EBC): a review of clinical study data. European Journal of Cancer, Supplement, 2010, 8, 72.	2.2	1
389	86 Oncoplastic surgery but not objectively measured symmetry after breast conserving therapy improves quality of life in breast cancer patients. European Journal of Cancer, Supplement, 2010, 8, 83.	2.2	0
390	HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Annals of Oncology, 2010, 21, 955-960.	0.6	49
391	PCN74 ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER CAN BE COST-EFFECTIVE FROM ITALIAN, SPANISH, AND PORTUGUESE HEALTH-CARE PERSPECTIVES, BASED ON THE ABCSG-12 TRIAL. Value in Health, 2010, 13, A265.	0.1	0
392	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. Journal of Clinical Oncology, 2010, 28, 509-518.	0.8	716
393	Closing in on the unknown enemy. Lancet Oncology, The, 2010, 11, 402-403.	5.1	1
394	10 years of ATAC: one question answered, many others unresolved. Lancet Oncology, The, 2010, 11, 1109-1110.	5.1	1
395	Abstract P5-11-02: The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests That the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy. , 2010, , .		1
396	Abstract PD01-03: Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer. , 2010, , .		6

#	ARTICLE	IF	CITATIONS
397	Abstract PD09-05: Impact of Body Mass Index (BMI) on the Efficacy of Endocrine Therapy in Postmenopausal Breast Cancer Patients – An Analysis of the ABCSG 6 and 6a Trial. , 2010, , .		3
398	Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology, 2010, 28, 512-512.	0.8	9
399	Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).. Journal of Clinical Oncology, 2010, 28, 530-530.	0.8	7
400	Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.. Journal of Clinical Oncology, 2010, 28, 533-533.	0.8	14
401	Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8.. Journal of Clinical Oncology, 2010, 28, 534-534.	0.8	0
402	Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)- positive metastatic breast cancer.. Journal of Clinical Oncology, 2010, 28, 1098-1098.	0.8	0
403	The evolving role of zoledronic acid in early breast cancer. OncoTargets and Therapy, 2009, 2, 95.	1.0	7
404	Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. New England Journal of Medicine, 2009, 360, 679-691.	13.9	976
405	Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. Clinical Cancer Research, 2009, 15, 5888-5894.	3.2	26
406	Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?. Therapeutic Advances in Medical Oncology, 2009, 1, 123-136.	1.4	5
407	Third consensus on medical treatment of metastatic breast cancer. Annals of Oncology, 2009, 20, 1771-1785.	0.6	178
408	Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio. Breast Care, 2009, 4, 155-161.	0.8	2
409	Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials. Current Cancer Drug Targets, 2009, 9, 824-833.	0.8	49
410	Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. Endocrine-Related Cancer, 2009, 16, 73-83.	1.6	4
411	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer, 2009, 9, 367.	1.1	22
412	Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There an Adjuvant Benefit?. Clinical Breast Cancer, 2009, 9, S18-S27.	1.1	11
413	0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy. Breast, 2009, 18, S53.	0.9	0
414	0156 Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial. Breast, 2009, 18, S59.	0.9	1

#	ARTICLE	IF	CITATIONS
415	0160 Dosing of zoledronic acid (ZOL) throughout the treatment continuum in patients (pts) with breast cancer (BC). <i>Breast</i> , 2009, 18, S60.	0.9	0
416	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 373-380.	1.1	9
417	Bisphosphonates as adjuvant therapy for breast cancer. <i>Current Breast Cancer Reports</i> , 2009, 1, 54-63.	0.5	5
418	To Measure the Unmeasurable. <i>World Journal of Surgery</i> , 2009, 33, 52-53.	0.8	0
419	Breast cancer chemoprevention - a vision not yet realized. <i>European Journal of Cancer Care</i> , 2009, 18, 438-446.	0.7	13
420	Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer. <i>European Journal of Surgical Oncology</i> , 2009, 35, 264-270.	0.5	75
421	4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). <i>European Journal of Cancer, Supplement</i> , 2009, 7, 3.	2.2	12
422	Bisphosphonates in the adjuvant treatment of early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, .	2.2	0
423	Fighting overtreatment in adjuvant breast cancer therapy. <i>Lancet, The</i> , 2009, 374, 2029-2030.	6.3	34
424	Cryopreservation of Monocytes Is Superior to Cryopreservation of Immature or Semi-mature Dendritic Cells for Dendritic Cell-based Immunotherapy. <i>Journal of Immunotherapy</i> , 2009, 32, 638-654.	1.2	14
425	New results from the use of bisphosphonates in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 213-218.	0.5	22
426	Adjuvant Chemotherapy of Breast Cancer. <i>Breast Care</i> , 2009, 4, 9-9.	0.8	0
427	Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Breast Cancer Online: BCO</i> , 2009, 12, .	0.1	0
428	Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. <i>Oncology Reports</i> , 2009, 21, 1585-92.	1.2	41
429	Endocrine Therapy Plus Zoledronic Acid in Premenopausal Breast Cancer. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 391-393.	0.2	0
430	Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC + Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer.. , 2009, , .		8
431	Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.. , 2009, , .		6
432	Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells. <i>Journal of Clinical Oncology</i> , 2009, 27, e22035-e22035.	0.8	0

#	ARTICLE	IF	CITATIONS
433	Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2009, 27, 1090-1090.	0.8	1
434	Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG-17). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 203-213.	1.1	34
435	The potential risk of neoadjuvant chemotherapy in breast cancer patientsâ€™ results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG-07). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 309-316.	1.1	28
436	Allogeneic tumor lysate can serve as both antigen source and protein supplementation for dendritic cell culture. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 859-870.	2.0	4
437	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 903-910.	1.1	42
438	(Neo)-adjuvant chemotherapy in breast cancer â€™ Trials, errors and new rationales from the SABCS 2007. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 23-26.	0.3	0
439	Cystic neoplasms of the pancreas: conservative or operative treatment?. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2008, 40, 220-226.	0.3	1
440	Low telomerase activity: Possible role in the progression of human medullary thyroid carcinoma. <i>European Journal of Cancer</i> , 2008, 44, 866-875.	1.3	14
441	The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2008, 34, 857-862.	0.5	13
442	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSCG-12 bone-mineral density substudy. <i>Lancet Oncology</i> , The, 2008, 9, 840-849.	5.1	345
443	Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774.	3.2	81
444	Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. <i>Annals of Oncology</i> , 2008, 19, 1837-1841.	0.6	17
445	Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 2082-2087.	3.2	28
446	Adjuvant Endocrine Therapy in Premenopausal Patients. <i>Breast Care</i> , 2008, 3, 311-316.	0.8	1
447	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008, 19, 420-432.	0.6	410
448	Breast-Conserving Therapy for Centrally Located Breast Cancer. <i>Annals of Surgery</i> , 2008, 247, 470-476.	2.1	49
449	Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSCG-12.. <i>Journal of Clinical Oncology</i> , 2008, 26, LBA4-LBA4.	0.8	57
450	The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in postmenopausal patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 1060-1060.	0.8	0

#	ARTICLE	IF	CITATIONS
451	Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1845-1853.	3.0	288
452	A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. <i>British Journal of Cancer</i> , 2007, 97, 1021-1027.	2.9	90
453	Managing Aromatase Inhibitor-Associated Bone Loss in Breast Cancer. <i>Women's Health</i> , 2007, 3, 441-448.	0.7	2
454	Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2007, 25, 2012-2018.	0.8	83
455	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007, 18, 215-225.	0.6	86
456	Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 820-828.	0.8	308
457	Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment. <i>Clinical Cancer Research</i> , 2007, 13, 4435-4439.	3.2	20
458	An oncoplastic procedure for central and medio-cranial breast cancer. <i>European Journal of Surgical Oncology</i> , 2007, 33, 1158-1163.	0.5	43
459	Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3853-3858.	0.8	144
460	Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 3859-3865.	0.8	505
461	Lumpectomy Plus Tamoxifen or Anastrozole With or Without Whole Breast Irradiation in Women With Favorable Early Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 334-340.	0.4	209
462	In Reply to Dr. Dizdar et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1651.	0.4	0
463	The use of a breast symmetry index for objective evaluation of breast cosmesis. <i>Breast</i> , 2007, 16, 429-435.	0.9	94
464	P76 Improving cosmetic outcome in central breast cancer: The use of oncoplastic techniques. <i>Breast</i> , 2007, 16, S34.	0.9	0
465	Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 45-52.	1.1	23
466	Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epirubicin and docetaxel+G-CSF. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 109-114.	1.1	40
467	Breast reconstruction – a view from surgical oncology. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007, 39, 295-298.	0.3	0
468	Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breast defects. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2007, 39, 330-339.	0.3	13

#	ARTICLE	IF	CITATIONS
469	Preoperative oxaliplatin (O), capecitabine (X), and external beam radiotherapy (RT) in patients (pts) with newly diagnosed, primary operable, locally advanced rectal cancer (LARC). <i>Journal of Clinical Oncology</i> , 2007, 25, 14527-14527.	0.8	1
470	Cyclin D1 expression in breast cancer patients and tamoxifen therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 523-523.	0.8	1
471	A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4052-4052.	0.8	0
472	Overexpression of the human homologue for <i>Caenorhabditis elegans</i> cul-4 gene is associated with poor outcome in node-negative breast cancer. <i>Anticancer Research</i> , 2007, 27, 949-52.	0.5	50
473	Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology</i> , The, 2006, 7, 991-996.	5.1	231
474	Inosine 5- α -monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells. <i>Clinica Chimica Acta</i> , 2006, 364, 139-147.	0.5	8
475	A Case of Phyllodes Tumor with Focal Transition into Low-Grade Lymphangiosarcoma. <i>Breast Care</i> , 2006, 1, 391-394.	0.8	1
476	Adjuvanter Einsatz von Trastuzumab (Herceptin [®]) in der klinischen Praxis au�erhalb von klinischen Studien. <i>Breast Care</i> , 2006, 1, 96-101.	0.8	0
477	The Endocrine Origin and Different Characters of Breast Cancers â€“ Recent Research on Hormone Receptors and Endocrine Treatment*. <i>Breast Care</i> , 2006, 1, 124-128.	0.8	0
478	Breast Centers Revisited â€“ a Critical Perspective. <i>Breast Care</i> , 2006, 1, 150-151.	0.8	0
479	Breast Cancer Chemoprevention â€“ not yet There. <i>Breast Care</i> , 2006, 1, 295-296.	0.8	0
480	Breast Conservation: Evolution of Surgical Strategies. <i>Breast Journal</i> , 2006, 12, S165-S173.	0.4	32
481	Aetiology and surgical management of toxic megacolon. <i>Colorectal Disease</i> , 2006, 8, 195-201.	0.7	54
482	Preoperative Core Needle Biopsy does not Increase Local Recurrence Rate in Breast Cancer Patients. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 9-15.	1.1	42
483	Hypoxia inducible factor-1 \pm correlates with VEGF-C expression and lymphangiogenesis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 135-141.	1.1	98
484	VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. <i>Surgery</i> , 2006, 139, 839-846.	1.0	142
485	Heat Shock Treatment of Tumor Lysate-Pulsed Dendritic Cells Enhances Their Capacity to Elicit Antitumor T Cell Responses against Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4571-4577.	1.8	24
486	Multidetector CT of Pancreas: Effects of Contrast Material Flow Rate and Individualized Scan Delay on Enhancement of Pancreas and Tumor Contrast. <i>Radiology</i> , 2006, 241, 441-448.	3.6	64

#	ARTICLE	IF	CITATIONS
487	Management of Bone Loss Induced by Aromatase Inhibitors. <i>Cancer Investigation</i> , 2006, 24, 328-330.	0.6	13
488	Bisphosphonates and the prevention of osteoporosis in the adjuvant setting. <i>Breast Cancer Online: BCO</i> , 2005, 8, .	0.1	0
489	Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 441-445.	0.7	12
490	Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, S2.	0.4	2
491	A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. <i>British Journal of Cancer</i> , 2005, 92, 1655-1662.	2.9	28
492	P81 Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. <i>Breast</i> , 2005, 14, S38.	0.9	25
493	Does Additional Doxorubicin Chemotherapy Improve Outcome in Patients with Hepatocellular Carcinoma Treated by Liver Transplantation?. <i>American Journal of Transplantation</i> , 2005, 5, 788-794.	2.6	60
494	Preoperative second-line chemotherapy induces objective responses in primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2005, 117, 48-52.	1.0	4
495	Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet, The</i> , 2005, 366, 455-462.	6.3	828
496	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005, 366, 2087-2106.	6.3	4,596
497	Fulvestrant (Faslodex™) in pre-treated patients with advanced breast cancer: A single-centre experience. <i>European Journal of Cancer</i> , 2005, 41, 2655-2661.	1.3	39
498	A multicenter phase II, open-label trial of multiple doses of cancer vaccine candidate IGN101 to evaluate efficacy against disseminated tumor cells in blood. <i>Journal of Clinical Oncology</i> , 2005, 23, 2557-2557.	0.8	4
499	Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). <i>Journal of Clinical Oncology</i> , 2005, 23, 527-527.	0.8	65
500	Retroviral targeting of proliferating endothelial cells. <i>Acta Biochimica Polonica</i> , 2005, 52, 731-5.	0.3	2
501	Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. <i>Anticancer Research</i> , 2005, 25, 4225-30.	0.5	3
502	Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. <i>International Journal of Oncology</i> , 2004, 24, 609.	1.4	40
503	Dendritic Cell Vaccination in Medullary Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 2944-2953.	3.2	58
504	The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2004, 36, 41-45.	0.3	3

#	ARTICLE	IF	CITATIONS
505	Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 26-31.	1.0	42
506	High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. <i>European Journal of Surgical Oncology</i> , 2004, 30, 243-247.	0.5	43
507	The evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 77.	2.2	1
508	Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer. <i>Annals of Surgery</i> , 2004, 240, 306-312.	2.1	232
509	Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. <i>Oncology Reports</i> , 2004, 12, 495.	1.2	13
510	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004, 22, 553-553.	0.8	13
511	6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. <i>Journal of Clinical Oncology</i> , 2004, 22, 553-553.	0.8	7
512	Gastrointestinal autonomic nerve tumors: A surgical point of view. <i>World Journal of Gastroenterology</i> , 2004, 10, 2447.	1.4	8
513	Effect of neoadjuvant chemotherapy with gemcitabine and docetaxel on 3-year survival and resection rate in previously unresectable locally advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 4234-4234.	0.8	2
514	Future Directions in the Treatment of Breast Cancer – Cellular Interventions Using Dendritic Cells. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 119-123.	1.1	0
515	Future Directions in the Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 117-118.	1.1	42
516	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 1-7.	1.1	36
517	Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 207-213.	1.1	53
518	Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene. <i>Langenbeck's Archives of Surgery</i> , 2003, 388, 3-8.	0.8	8
519	Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2003, 35, 342-343.	0.3	0
520	The prognostic influence of body mass index in premenopausal breast cancer patients. <i>Breast</i> , 2003, 12, S18.	0.9	1
521	Assessment of her2-neu status in core needle biopsy of 215 patients with primary breast cancer. <i>Breast</i> , 2003, 12, S28.	0.9	0
522	Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. <i>Cancer</i> , 2003, 98, 2291-2301.	2.0	16

#	ARTICLE	IF	CITATIONS
523	Do we need HER-2/neutesting for all patients with primary breast carcinoma?. <i>Cancer</i> , 2003, 98, 2547-2553.	2.0	85
524	Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. <i>International Journal of Cancer</i> , 2003, 104, 677-682.	2.3	135
525	Exact Log-Rank Tests for Unequal Follow-Up. <i>Biometrics</i> , 2003, 59, 1151-1157.	0.8	54
526	Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6. <i>Journal of Clinical Oncology</i> , 2003, 21, 984-990.	0.8	52
527	Dendritic Cell-Based Vaccination in Solid Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 135-142.	0.8	124
528	Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.. <i>Endocrine-Related Cancer</i> , 2003, 10, 91-98.	1.6	62
529	Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells. <i>International Journal of Oncology</i> , 2003, 22, 1397.	1.4	17
530	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 556-564.	2.1	15
531	Significant Increase in Breast Conservation in 16 Years of Trials Conducted by the Austrian Breast & Colorectal Cancer Study Group. <i>Annals of Surgery</i> , 2003, 237, 556-564.	2.1	24
532	Impact of pretreatment thrombocytosis on survival in primary breast cancer. <i>Thrombosis and Haemostasis</i> , 2003, 89, 1098-1106.	1.8	124
533	Randomised Trial: One Cycle of Anthracycline-Containing Adjuvant Chemotherapy Compared with Six Cycles of CMF Treatment in Node-Positive, Hormone Receptor-Negative Breast Cancer Patients. <i>Oncology Research and Treatment</i> , 2003, 26, 115-119.	0.8	2
534	In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. <i>International Journal of Oncology</i> , 2003, 22, 651-6.	1.4	4
535	Stereotactic 11-Gauge Vacuum-Assisted Breast Biopsy: A Validation Study. <i>American Journal of Roentgenology</i> , 2002, 179, 1503-1507.	1.0	136
536	Stimulation of Autologous Antitumor T-Cell Responses Against Medullary Thyroid Carcinoma Using Tumor Lysate-Pulsed Dendritic Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1098-1104.	1.8	28
537	Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. <i>Journal of Clinical Oncology</i> , 2002, 20, 4621-4627.	0.8	271
538	Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. <i>Anti-Cancer Drugs</i> , 2002, 13, 67-74.	0.7	21
539	Young Age as an Independent Adverse Prognostic Factor in Premenopausal Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2002, 3, 65-72.	1.1	89
540	Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 155-159.	1.1	15

#	ARTICLE	IF	CITATIONS
541	Intraductal papillary-mucinous adenoma associated with unusual focal fibromatosis: a postoperative stromal nodule. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 308-311.	1.4	18
542	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1831-7.	3.2	312
543	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. <i>Anti-Cancer Drugs</i> , 2001, 12, 209-212.	0.7	10
544	Contralateral Breast Cancer: Molecular Differentiation Between Metastasis and Second Primary Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 67, 1-8.	1.1	55
545	Prognostic relevance of three histological grading methods in breast cancer. <i>International Journal of Oncology</i> , 2001, 19, 1271.	1.4	7
546	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2001, 85, 1850-1852.	2.9	36
547	Heat treatment of hepatocellular carcinoma cells: increased levels of heat shock proteins 70 and 90 correlate with cellular necrosis. <i>Anticancer Research</i> , 2001, 21, 295-300.	0.5	13
548	Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. <i>Clinical Cancer Research</i> , 2001, 7, 1669-75.	3.2	114
549	Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. <i>Cancer Gene Therapy</i> , 2000, 7, 66-73.	2.2	152
550	Die axillare Lymphknotendisektion in der Therapie des Mammakarzinoms. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2000, 32, 119-123.	0.3	0
551	EFFECTS OF HYPERTHERMIA AND TUMOUR NECROSIS FACTOR ON INFLAMMATORY CYTOKINE SECRETION AND PROCOAGULANT ACTIVITY IN ENDOTHELIAL CELLS. <i>Cytokine</i> , 2000, 12, 339-347.	1.4	42
552	TUMOUR NECROSIS FACTOR RECEPTOR I (p55) IS UPREGULATED ON ENDOTHELIAL CELLS BY EXPOSURE TO THE TUMOUR-DERIVED CYTOKINE ENDOTHELIAL MONOCYTE-ACTIVATING POLYPEPTIDE II (EMAP-II). <i>Cytokine</i> , 2000, 12, 992-1000.	1.4	42
553	The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing. <i>Journal of Surgical Research</i> , 2000, 91, 26-31.	0.8	121
554	Percutaneous endoscopic gastrostomy: Results and complications of a retrospective analysis of 53 patients. <i>Gastroenterology</i> , 2000, 118, A1081.	0.6	0
555	TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. <i>Clinical Cancer Research</i> , 2000, 6, 50-6.	3.2	196
556	Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. <i>Anticancer Research</i> , 2000, 20, 4599-604.	0.5	9
557	Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1701-1701.	0.8	28
558	Thymidine Kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector for Tumor-Directed Gene Therapy. <i>Human Gene Therapy</i> , 1999, 10, 649-657.	1.4	90

#	ARTICLE	IF	CITATIONS
559	Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. <i>European Journal of Cancer</i> , 1999, 35, 398-405.	1.3	34
560	Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSC) trial 5. <i>European Journal of Cancer</i> , 1999, 35, S83.	1.3	37
561	Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature. <i>Surgery</i> , 1999, 126, 890-899.	1.0	28
562	Induction of Immunomediated Diseases by Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor During Cancer Treatment?. <i>Journal of Immunotherapy</i> , 1999, 22, 85-89.	1.2	2
563	Regional Versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases. <i>Annals of Surgery</i> , 1999, 230, 352.	2.1	33
564	Die Chirurgie des Mammacarcinoms. <i>Onkologie Heute</i> , 1999, , 27-37.	0.0	0
565	Experimentelle Therapie von Lebermetastasen. <i>Onkologie Heute</i> , 1999, , 167-174.	0.0	0
566	In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). <i>Cancer Research</i> , 1999, 59, 205-12.	0.4	34
567	It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 37-46.	1.1	59
568	Tamoxifen for early breast cancer: an overview of the randomised trials. <i>Lancet, The</i> , 1998, 351, 1451-1467.	6.3	3,829
569	Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. <i>European Journal of Cancer</i> , 1998, 34, 66-70.	1.3	10
570	P60 Adjuvant radiotherapy has no benefit after primary breast cancer treatment in selected postmenopausal patients. <i>European Journal of Cancer</i> , 1998, 34, S31.	1.3	2
571	Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. <i>Journal of Hepatology</i> , 1998, 28, 497-503.	1.8	14
572	Evaluation of needle size for breast biopsy: comparison of 14-, 16-, and 18-gauge biopsy needles. <i>American Journal of Roentgenology</i> , 1998, 171, 59-63.	1.0	64
573	Outcomes of Surgical, Percutaneous Endoscopic, and Percutaneous Radiologic Gastrostomies. <i>Archives of Surgery</i> , 1998, 133, 1076.	2.3	140
574	<i>Haemophilus parainfluenzae</i> Liver Abscess after Successful Liver Transplantation. <i>Journal of Clinical Microbiology</i> , 1998, 36, 818-819.	1.8	17
575	Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. <i>Radiology</i> , 1997, 202, 421-429.	3.6	62
576	p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. <i>European Journal of Cancer</i> , 1997, 33, 39-44.	1.3	76

#	ARTICLE	IF	CITATIONS
577	Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem Mammakarzinom (II). <i>Acta Chirurgica Austriaca</i> , 1997, 29, 62-67.	0.2	4
578	The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 317-324.	1.2	0
579	Neoadjuvant Chemotherapy Enables Breast-Conserving Surgery in Patients with Very Large Breast Cancers: Preliminary Results. <i>Oncology Research and Treatment</i> , 1996, 19, 242-246.	0.8	4
580	Tumor recurrence after oLTX. <i>Transplant International</i> , 1996, 9, S151-S154.	0.8	5
581	Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1996, 111, 827-832.	0.4	22
582	THE IMPORTANCE OF THE EFFECT OF UNDERLYING DISEASE ON REJECTION OUTCOMES FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 554-560.	0.5	48
583	Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer. <i>British Journal of Cancer</i> , 1995, 72, 51-55.	2.9	42
584	Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity?. <i>Breast Cancer Research and Treatment</i> , 1995, 34, 213-219.	1.1	10
585	Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. <i>Thrombosis Research</i> , 1995, 80, 225-233.	0.8	2
586	Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 165-175.	1.1	53
587	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon-2b in advanced colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 314-318.	1.2	3
588	Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst all ICUS of a transplant centre. <i>Transplant International</i> , 1994, 7, 668-671.	0.8	2
589	The Potential Impact of Tamoxifen in Breast Cancer Prevention. <i>Oncology Research and Treatment</i> , 1993, 16, 297-303.	0.8	1
590	Circulating ICAM-1: novel parameter of renal graft rejection. <i>Transplantation Proceedings</i> , 1993, 25, 919-20.	0.3	22
591	Impact of donor cause of death on renal graft function—a multivariate analysis of 1545 kidney transplants. <i>Transplantation Proceedings</i> , 1993, 25, 3102-3.	0.3	4
592	What do intensive care unit personnel think about organ donation? Opinion poll amongst transplant centers. <i>Transplantation Proceedings</i> , 1993, 25, 3122-3.	0.3	4
593	Impact of vesicoureteral reflux on graft survival in renal transplantation. <i>Transplantation Proceedings</i> , 1993, 25, 1058-9.	0.3	17
594	DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. <i>European Journal of Cancer</i> , 1992, 28, 711-716.	1.3	29

#	ARTICLE	IF	CITATIONS
595	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. <i>Transplant International</i> , 1992, 5, S116-S120.	0.8	9
596	Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 629-634.	1.2	16
597	Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. <i>International Journal of Cancer</i> , 1992, 52, 707-712.	2.3	33
598	Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. , 1992, 5 Suppl 1, 116-120.		5
599	Cadaveric kidney donation beyond the age of 60 years " a comparative analysis of 1180 grafts from different donor age groups. , 1992, 5 Suppl 1, 47-50.		0
600	Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1991, 23, 2269-71.	0.3	11
601	Soluble interleukin-2 receptor in liver transplant recipients. <i>Transplantation Proceedings</i> , 1991, 23, 1417-8.	0.3	3
602	Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver?. <i>Transplantation Proceedings</i> , 1991, 23, 1567-8.	0.3	66
603	PANCREATIC TRANSPLANTATION WITH VENOUS PORTAL DRAINAGE. <i>Lancet, The</i> , 1989, 334, 988.	6.3	7
604	Chirurgische Probleme der Lebertransplantation. <i>Intensivmedizinisches Seminar</i> , 1989, , 117-123.	0.0	0
605	OKT3 immunoprophylaxis in human liver transplantation. <i>Transplantation Proceedings</i> , 1989, 21, 2253-4.	0.3	7
606	Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSCG). <i>Breast Care</i> , 0, , 1-9.	0.8	0
607	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. , 0, .		1
608	Indikationsstellung und Technik der Brusterhaltenden Operation. , 0, , 61-79.		0
609	Operative Taktik und Technik nach PrÄoperativer Chemotherapie. , 0, , 125-136.		0